Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline landscape is provided which includes the disease overview and Lambert-Eaton Myasthenic Syndrome (LEMS) treatment guidelines. The assessment part of the report embraces, in depth Lambert-Eaton Myasthenic Syndrome (LEMS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lambert-Eaton Myasthenic Syndrome (LEMS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lambert-Eaton Myasthenic Syndrome (LEMS) Understanding
According to the Muscular Dystrophy Association, Lambert–Eaton myasthenic syndrome (LEMS) also known as Lambert-Eaton Syndrome is an autoimmune disease in which the immune system attacks the body’s own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. LEMS is characterized by weakness and fatigue especially of the muscles in the legs and arms. LEMS can affect many muscles, but usually, it causes weakness mostly in the upper legs and hips more than the upper arms and shoulders. These proximal muscles are more likely to fatigue with use, and muscle fatigue and sometimes stiffness may be more prominent than actual weakness. The legs are particularly affected. There may be difficulty getting out of a chair, going up stairs, running, or walking. Lifting and pushing may be difficult.
Lambert-Eaton Myasthenic Syndrome (LEMS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lambert-Eaton Myasthenic Syndrome (LEMS) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline report covers 2+ companies. Some of the key players include Shenox Pharmaceuticals (SHX 003) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Lambert-Eaton Myasthenic Syndrome (LEMS) Analytical Perspective by DelveInsight
Scope of the report
"Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline landscape is provided which includes the disease overview and Lambert-Eaton Myasthenic Syndrome (LEMS) treatment guidelines. The assessment part of the report embraces, in depth Lambert-Eaton Myasthenic Syndrome (LEMS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lambert-Eaton Myasthenic Syndrome (LEMS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lambert-Eaton Myasthenic Syndrome (LEMS) Understanding
According to the Muscular Dystrophy Association, Lambert–Eaton myasthenic syndrome (LEMS) also known as Lambert-Eaton Syndrome is an autoimmune disease in which the immune system attacks the body’s own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. LEMS is characterized by weakness and fatigue especially of the muscles in the legs and arms. LEMS can affect many muscles, but usually, it causes weakness mostly in the upper legs and hips more than the upper arms and shoulders. These proximal muscles are more likely to fatigue with use, and muscle fatigue and sometimes stiffness may be more prominent than actual weakness. The legs are particularly affected. There may be difficulty getting out of a chair, going up stairs, running, or walking. Lifting and pushing may be difficult.
Lambert-Eaton Myasthenic Syndrome (LEMS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lambert-Eaton Myasthenic Syndrome (LEMS) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline report covers 2+ companies. Some of the key players include Shenox Pharmaceuticals (SHX 003) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Lambert-Eaton Myasthenic Syndrome (LEMS) Analytical Perspective by DelveInsight
- In-depth Lambert-Eaton Myasthenic Syndrome Commercial Assessment of products
- Lambert-Eaton Myasthenic Syndrome Clinical Assessment of products
Scope of the report
- The Lambert-Eaton Myasthenic Syndrome report provides an overview of therapeutic pipeline activity for Lambert-Eaton Myasthenic Syndrome across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Lambert-Eaton Myasthenic Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Lambert-Eaton Myasthenic Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lambert-Eaton Myasthenic Syndrome
- Establish a comprehensive understanding of the current pipeline scenario across Lambert-Eaton Myasthenic Syndrome to formulate effective R&D strategies
- Assess challenges and opportunities that influence Lambert-Eaton Myasthenic Syndrome R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Lambert-Eaton Myasthenic Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lambert-Eaton Myasthenic Syndrome to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)
2.1. Lambert-Eaton Myasthenic Syndrome (LEMS) Disease Overview
2.2. Lambert-Eaton Myasthenic Syndrome (LEMS) History
2.3. Lambert-Eaton Myasthenic Syndrome (LEMS) Symptoms
2.4. Lambert-Eaton Myasthenic Syndrome (LEMS) Causes
2.5. Lambert-Eaton Myasthenic Syndrome (LEMS) Pathophysiology
2.6. Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosis
2.6.1. Diagnostic Guidelines
3. LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Lambert-Eaton Myasthenic Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Lambert-Eaton Myasthenic Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. LAMBERT-EATON MYASTHENIC SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. LAMBERT-EATON MYASTHENIC SYNDROME-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. SHX 003- Shenox Pharmaceuticals
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. LAMBERT-EATON MYASTHENIC SYNDROME KEY COMPANIES
8.1. Ruzurgi
8.2. SHX 003
9. LAMBERT-EATON MYASTHENIC SYNDROME KEY PRODUCTS
9.1. Jacobus Pharmaceutical
9.2. Shenox Pharmaceuticals
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. LAMBERT-EATON MYASTHENIC SYNDROME- UNMET NEEDS
12. LAMBERT-EATON MYASTHENIC SYNDROME - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)
2.1. Lambert-Eaton Myasthenic Syndrome (LEMS) Disease Overview
2.2. Lambert-Eaton Myasthenic Syndrome (LEMS) History
2.3. Lambert-Eaton Myasthenic Syndrome (LEMS) Symptoms
2.4. Lambert-Eaton Myasthenic Syndrome (LEMS) Causes
2.5. Lambert-Eaton Myasthenic Syndrome (LEMS) Pathophysiology
2.6. Lambert-Eaton Myasthenic Syndrome (LEMS) Diagnosis
2.6.1. Diagnostic Guidelines
3. LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Lambert-Eaton Myasthenic Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Lambert-Eaton Myasthenic Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. LAMBERT-EATON MYASTHENIC SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. LAMBERT-EATON MYASTHENIC SYNDROME-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. SHX 003- Shenox Pharmaceuticals
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. LAMBERT-EATON MYASTHENIC SYNDROME KEY COMPANIES
8.1. Ruzurgi
8.2. SHX 003
9. LAMBERT-EATON MYASTHENIC SYNDROME KEY PRODUCTS
9.1. Jacobus Pharmaceutical
9.2. Shenox Pharmaceuticals
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. LAMBERT-EATON MYASTHENIC SYNDROME- UNMET NEEDS
12. LAMBERT-EATON MYASTHENIC SYNDROME - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Lambert-Eaton Myasthenic Syndrome Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Lambert-Eaton Myasthenic Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Lambert-Eaton Myasthenic Syndrome Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Lambert-Eaton Myasthenic Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Lambert-Eaton Myasthenic Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Lambert-Eaton Myasthenic Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
BioMarin
Jacobus Pharmaceutical
Shenox Pharmaceuticals
Catalyst Pharmaceuticals
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Lambert-Eaton Myasthenic Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Lambert-Eaton Myasthenic Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
BioMarin
Jacobus Pharmaceutical
Shenox Pharmaceuticals
Catalyst Pharmaceuticals
